Thus, it has been described that plasma EV concentration is higher in glioblastoma patients compared to healthy controls and that the proteomic profiling of these EVs revealed a glioblastoma-distinctive signature with EGFR amplifications, PTEN deletions, and IDH1/2 and TP53 mutations [41]. Here, IDH1 is linked to glioblastoma.